Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2–Associated Acute Respiratory Failure
Restricted accessResearch articleFirst published online April, 2022
Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2–Associated Acute Respiratory Failure
Extracorporeal membrane oxygenation (ECMO) is a potential option for the management of severe acute respiratory failure secondary to COVID-19. Conflicting the use of this therapy is the known coagulopathy within COVID-19, leading to an incidence of venous thrombotic events of 25% to 49%. To date, limited guidance is available on optimal anticoagulation strategies in this population.
Objective
The purpose of this study was to evaluate the utilization of a pharmacist-driven bivalirudin dosing protocol for anticoagulation in the setting of ECMO for COVID-19–associated respiratory failure.
Methods
This was a single-center retrospective chart review over a 9-month period of patients receiving bivalirudin while on ECMO. All patients with acute respiratory failure requiring ECMO with a positive SARS-CoV-2 polymerase chain reaction were included. Bivalirudin was dosed via aPTT monitoring after a starting dose of 0.2 or 0.3 mg/kg/h.
Results
There were 33 patients included in this study, all receiving mechanical ventilation. The most common starting dose of bivalirudin was 0.2 mg/kg/h, with an average time to therapeutic range of 20 hours. Compared to previous reports, rates of bleeding were low at 15.1%, and 6.1% of patients developed a new venous thromboembolic event while on ECMO. ECMO survival was 51.5%, with an ICU mortality rate of 48.5%.
Conclusion and Relevance
In the first published report of its use within this population, bivalirudin was found to be a viable choice for anticoagulation in those patients on ECMO for severe respiratory failure secondary to COVID-19.
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Published February 2, 2021. Accessed February 28, 2021. https://covid19.who.int/
2.
MengLQiuHWanL, et al. Intubation and ventilation amid the COVID-19 outbreak: Wuhan’s experience. Anesthesiology. 2020;132:1317-1332. doi:10.1097/ALN.0000000000003296
3.
WunschH.Mechanical ventilation in COVID-19: interpreting the current epidemiology. Am J Respir Crit Care Med. 2020;202:1-4. doi:10.1164/rccm.202004-1385ED
4.
WuZMcGooganJM.Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242. doi:10.1001/jama.2020.2648
5.
KowalewskiMFinaDSlomkaA.COVID-19 and ECMO: the interplay between coagulation and inflammation—a narrative review. Crit Care. 2020;24:205. doi:10.1186/s13054-020-02925-3
ZengYCaiZXianyuYYangBXSongTYanQ.Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care. 2020;24:148. doi:10.1186/s13054-020-2840-8
8.
HenryBMLippiG.Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care. 2020;58:27-28. doi:10.1016/j.jcrc.2020.03.011
9.
JäckelMRilingerJLangCN, et al. Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza: a single-center registry study. Artif Organs. 2021;45:593-601. doi:10.1111/aor.13865
10.
ShihESquiersJJDiMaioJM, et al. Outcomes of extracorporeal membrane oxygenation in patients with severe acute respiratory distress syndrome caused by COVID-19 versus influenza. Ann Thorac Surg. Published online June 14, 2021. doi:10.1016/j.athoracsur.2021.05.060
11.
HemkerHC.A century of heparin: past, present and future. J Thromb Haemost. 2016;14:2329-2338. doi:10.1111/jth.13555
12.
PanigadaMSpinelliECucinoA, et al. Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial. Trials. 2019;20:349. doi:10.1186/s13063-019-3386-4
13.
ChoiJHLucJGYWeberMP, et al. Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. Ann Cardiothorac Surg. 2019;8:19-31. doi:10.21037/acs.2018.12.0
14.
McFadyenJDStevensHPeterK.The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127:571-587. doi:10.1161/CIRCRESAHA.120.317447
15.
GardnerAJKirkinDJRodriguez-VillarSLeoz AbellanasGTeeAValentinA.Antithrombin III deficiency-induced coagulopathy in the context of COVID-19: a case series. Br J Haematol. Published online May 30, 2021. doi:10.1111/bjh.17575
JizziniMShahMZhouK.SARS-CoV-2 and anti-cardiolipin antibodies. Clin Med Insights Case Rep. 2020;13: 1179547620980381. doi:10.1177/1179547620980381
18.
ShekarKBadulakJPeekG, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers. ASAIO J. 2020;66:707-721. doi:10.1097/MAT.0000000000001193
19.
KonZNSmithDEChangSH, et al. Extracorporeal membrane oxygenation support in severe COVID-19. Ann Thorac Surg. 2021;111:537-543. doi:10.1016/j.athoracsur.2020.07.002
20.
SeelhammerTGRowsePYalamuriS.Bivalirudin for maintenance anticoagulation during venovenous extracorporeal membrane oxygenation for COVID-19. J Cardiothorac Vasc Anesth. 2020;35:1149-1153. doi:10.1053/j.jvca.2020.06.059
21.
SmithNTrigonisRRahmanO, et al. Bivalirudin as therapeutic anticoagulation in COVID-19 patients on ECMO. ASAIO J. 2020;66(suppl 3):15.
MehranRRaoSVBhattDL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747. doi:10.1161/CIRCULATIONAHA.110.009449
26.
HamzahMJardenAMEzetenduCStewartR.Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2020;21:827-834. doi:10.1097/PCC.0000000000002384
27.
BereiTJLillybladMPWilsonKJGarberichRFHryniewiczKM.Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation. ASAIO J. 2018;64:623-629. doi:10.1097/MAT.0000000000000691
28.
RanucciMBallottaAKandilH, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275. doi:10.1186/cc10556
29.
TangNLiDWangXSunZ.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-847. doi:10.1111/jth.14768
30.
BowlesLPlattonS.YarteyN, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020;383:288-290. doi:10.1056/NEJMc2013656
31.
DurakKKerstenAGrottkeO, et al. Thromboembolic and bleeding events in COVID-19 patients receiving extracorporeal membrane oxygenation. Thorac Cardiovasc Surg. Published online April 16, 2021. doi:10.1055/s-0041-1725180
32.
RipollBRubinoABesserM, et al. Observational study of thrombosis and bleeding in COVID-19 VV ECMO patients. Int J Artif Organs. Published online January 28, 2021. doi:10.1177/0391398821989065
